 |
|
Welcome to EpiTherapeutics |
|
EpiTherapeutics is a newly established Danish biotech company originating from the BRIC research center at University of Copenhagen.
Behind the startup is a group of scientists headed by the Director of BRIC, Professor Kristian Helin.
The scientific discoveries of EpiTherapeutics have potential applications in a wide range of clinical indications, but the company's initial focus will be in oncology.
EpiTherapeutics' development programs are focused on enzymes involved in the regulation of transcription in cancer. Subsequent developments may identify other potential clinical indications.
EpiTherapeutics is funded by two of the leading Danish life science investor groups, Novo and SEED Capital Denmark to advance the discovery and development of new cancer treatments by leveraging breakthroughs in the field of Epigenetics.
|
|
|
